Alpha blockers in the management of acute urinary retention in prostatomegaly: a prospective observational study | ||||
| Egyptian Pharmaceutical Journal | ||||
| Article 3, Volume 24, Issue 1, January 2025, Page 17-28 PDF (2.29 MB) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/epj.2025.402395 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
| Hemraj S. Rajput1; Neel Shah2; Kalp Mehta1; Janki Parsaniya1; Jinal Patel1; Rajesh Hadia1 | ||||
| 1Department of Pharmacy, Sumandeep Vidyapeeth Deemed to be University, Vadodara, Gujarat, India | ||||
| 2Department of Urology, SBKS Medical Institute, and Research Centre, Sumandeep Vidyapeeth Deemed to be University, Vadodara, Gujarat, India | ||||
| Abstract | ||||
| Background Acute urinary retention (AUR) from prostatomegaly presents clinical challenges. Alpha blockers like tamsulosin and silodosin effectively alleviate AUR symptoms by relaxing bladder and prostate smooth muscles, and enhancing urine flow. Objective The study aims to assess the incidence of AUR in prostatomegaly patients, compare the efficacy of various alpha blockers in AUR management, and investigate associated side effects and adverse drug reactions. Patients and methods A total of 60 patients with confirmed prostatomegaly-induced AUR, determined by ultrasonography, were enrolled. The study evaluated the efficacy of alpha-blockers through pre- and postultrasonography assessments of prostate size and regular follow-ups at different intervals (5, 7, 8, and 15 days). Statistical analysis, including paired t-tests, was conducted to compare the efficacy of tamsulosin and silodosin. Result and conclusion Tamsulosin and silodosin were compared, revealing a significant reduction in prostate size for both drugs. However, tamsulosin demonstrated a greater paired difference (11.16) compared with silodosin (9.96). Cohen’s D values further supported the superior efficacy of tamsulosin (2.52) over silodosin (1.49). Tamsulosin also exhibited fewer side effects (five patients) compared with silodosin (eight patients), establishing it as the more effective alpha-blocker with minimal side effects in AUR with prostatomegaly patients. Patients aged 61–70 and smokers showed increased AUR risk. Tamsulosin outperformed silodosin in reducing prostate size, relieving AUR symptoms, and minimizing side effects, demonstrating effectiveness in AUR management. | ||||
| Keywords | ||||
| acute urinary retention; alpha blocker; prostatomegaly; silodosin; tamsulosin | ||||
|
Statistics Article View: 132 PDF Download: 223 |
||||
